"No point chatting to BP if you don't know what the selling price is going to be (i.e. $2,500 or $6,000 per course)"
I offer a slightly different perspective based on benefits of pain duration. This has massive TAM for a BP that is irrespective of DMOAD label. The only difference I see may be the potential upfront component if a deal was struck now or in 6-9 months. The risks is that PAR may not get clear direction from FDA or asked to run separate longitudinal studies. Either way the deal structure can cater for contingent outcomes.
IMO PAR will (rather than may) consider a regional deal over the coming months if it's a win/win. This is what our consultants have been engaged to achieve and they have been very busy is my understanding.
PAR. SP, page-309
-
- There are more pages in this discussion • 944 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.020(9.76%) |
Mkt cap ! $78.73M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.5¢ | 21.0¢ | $142.6K | 653.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16172 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 106589 | 6 |
View Market Depth
| Last trade - 13.19pm 04/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |